-+ 0.00%
-+ 0.00%
-+ 0.00%

Zoetis (ZTS) Won USDA Approval For A Three In One Poultry Vaccine

Simply Wall St·11/19/2026 17:08:42
Listen to the news
  • Zoetis (NYSE:ZTS) received a USDA license for Poulvac Procerta HVT-ND-ILT, a new three-in-one poultry vaccine.
  • The single-dose vector vaccine targets Marek’s disease, Newcastle disease, and infectious laryngotracheitis in commercial poultry flocks.
  • Poulvac Procerta HVT-ND-ILT expands Zoetis' poultry vaccine range for veterinarians and producers managing economically important flock health issues.
  • This new Poulvac Procerta HVT-ND-ILT approval only captures one angle of the Zoetis story today. Take a look at 1 warning sign we have identified for Zoetis.

For a wider view on where animal health and data-driven medicine are intersecting, it is worth exploring 37 healthcare AI stocks.

NYSE:ZTS Earnings & Revenue Growth as at Nov 2026
NYSE:ZTS Earnings & Revenue Growth as at Nov 2026

Zoetis, a US pharmaceuticals group with a market value of about $33.9b, focuses on medicines, vaccines, diagnostics and data tools for animal health. A three-disease poultry shot fits directly into its push to bundle biological products with broader flock management solutions.

4 things going right for Zoetis that this headline doesn't cover.

Zoetis investors get more proof of the “platform” animal health story, but poultry reliance cuts both ways

This poultry vaccine license leans into the bull case that Zoetis can keep widening its animal health platform across both pets and livestock, not just depend on U.S. companion animal spending. It lines up with the Narrative’s catalyst around unmet demand and global protein consumption supporting a broader revenue base, at a time when Global Companion Animal revenue recently showed a 6% decline and pricing pressure in dermatology is in focus. Poulvac Procerta HVT-ND-ILT also reinforces the idea that vaccines and biologics can help offset pressure where gross to net investments and rebates are heavier in older product franchises.

See how these catalysts shape Zoetis' path to a $88.38 fair value.

To see whether this actually shifts the balance toward the bullish side, watch Zoetis’ upcoming quarterly reports for poultry and wider livestock trends, especially any disclosed contribution from new vaccines and commentary on how livestock and international demand are tracking against softer U.S. companion animal volumes.

Add Zoetis to your Watchlist and get alerts as these catalysts play out.